Amyloid-beta-targeted monoclonal antibodies probably resulted in little to no difference in cognitive function or in dementia severity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results